Episode 258 - Susan Hill CEO & Board Member at Mestag Therapeutics
From The BioHub - by Avetix · · 36 min
This plays from the publisher's own server. We do not host a copy.
Description
We were delighted to be joined by Susan Hill, CEO and founder of Mestag Therapeutics, a biotechnology company pioneering new approaches to treating cancer and inflammatory diseases through the emerging field of fibroblast immunology.
Susan brings more than 25 years of experience across the biotechnology, pharmaceutical and investment industries. She has held senior leadership positions at Merck KGaA, Alexion, Freeline Therapeutics and Gyroscope Therapeutics, where she served as Chief Business Officer before its acquisition by Novartis.
She founded Mestag Therapeutics in 2020, building the company around some fascinating science and leading it through significant financing, strategic pharmaceutical partnerships and its evolution into a clinical-stage biotech.
Mestag is tackling an area of biology that has historically been overlooked, exploring how fibroblasts interact with the immune system and how those interactions could unlock entirely new therapeutic approaches for patients.
Today, we'll be discussing Susan's journey through the field, the experience of building and scaling biotech companies, the science behind Mestag, and what it takes to translate emerging biology into impactful medicines.